Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: The case of indomethacin

AAPS PharmSciTech

Volumn 9, Issue 1, 2008, Pages 146-153

  Bahl, Deepak ^a   Bogner, Robin H ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Amorphization; Co grinding; Dissolution; Indomethacin; Silicate; Solubility

Indexed keywords

ALUMINUM; GAMMA INDOMETACIN; HYDROCHLORIC ACID; INDOMETACIN; INDOMETACIN DERIVATIVE; MAGNESIUM ION; PHOSPHATE; SILICATE; SILICIC ACID; UNCLASSIFIED DRUG; WATER; DRUG CARRIER; EXCIPIENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACIDITY; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MIXTURE; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; PH; ROOM TEMPERATURE; X RAY DIFFRACTION; CHEMISTRY; DIFFUSION; DRUG SCREENING; MATERIALS TESTING; METHODOLOGY; SOLUBILITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIFFUSION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; EXCIPIENTS; INDOMETHACIN; MATERIALS TESTING; SILICATES; SOLUBILITY;

EID: 44849131724     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-007-9013-9     Document Type: Article

References (36)

1. B. C. Hancock, and G. Zografi. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 861:1-12 (1997).
2. W. L. Chiou, and S. Riegelman. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 609:1281-1302 (1971).
3. B. C. Hancock, and M. Parks. What is the true solubility advantage for amorphous pharmaceuticals? Pharma. Res. 174:397-404 (2000).
4. M. Kinoshita, K. Baba, A. Nagayasu, K. Yamabe, T. Shimooka, Y. I. Takeichi, M. Azuma, H. Houchi, and K. Minakuchi. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J. Pharm. Sci. 912:362-370 (2002).
5. T. Watanabe, S. Hasegawa, N. Wakiyama, A. Kusai, and M. Senna. Prediction of apparent equilibrium solubility of indomethacin compounded with silica by 13C solid state NMR. Int. J. Pharm. 2481-2:123-129 (2002).
6. T. Watanabe, S. Hasegawa, N. Wakiyama, A. Kusai, and M. Senna. Comparison between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion. Int. J. Pharm. 2501:283-286 (2003).
7. D. Law, E. A. Schmitt, K. C. Marsh, E. A. Everitt, W. Wang, J. J. Fort, S. L. Krill, and Y. Qiu. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J. Pharm. Sci. 933:563-570 (2004).
8. T. Watanabe, N. Wakiyama, F. Usui, M. Ikeda, T. Isobe, and M. Senna. Stability of amorphous indomethacin compounded with silica. Int. J. Pharm. 2261-2:81-91 (2001).
9. P. Tong, and G. Zografi. A study of amorphous molecular dispersions of indomethacin and its sodium salt. J. Pharm. Sci. 9012:1991-2004 (2001).
10. A. E. H. Gassim, P. G. Takla, and K. C. James. Polymorphism and possible intramolecular bonding in benperidol. Int. J. Pharm. 341-2: 23-28 (1986).
11. E. Nuernberg, and A. Hopp. Pharmaceutical studies of paracetamol. 2. Differential thermal analytical studies. Pharm. Ind. 451:85-87 (1983).
12. K. Y. Yang, R. Glemza, and C. I. Jarowski. Effects of amorphous silicon dioxides on drug dissolution. J. Pharm. Sci. 685:560-565 (1979).
13. P. Tong, and G. Zografi. Solid-state characteristics of amorphous sodium indomethacin relative to its free acid. Pharma Res. 168:1186-1192 (1999).
14. E. Yonemochi, S. Kitahara, S. Maeda, S. Yamamura, T. Oguchi, and K. Yamamoto. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur. J. Pharm. Sci. 74:331-338 (1999).
15. H. Takeuchi, S. Nagira, H. Yamamoto, and Y. Kawashima. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int. J. Pharm. 2931-2:155-164 (2005).
16. M. Ohta, and G. Buckton. A study of the differences between two amorphous spray-dried samples of cefditoren pivoxil which exhibited different physical stabilities. Int. J. Pharm. 2891-2:31-38 (2005).
17. D. J. Van Drooge, W. L. J. Hinrichs, H. W. Frijlink, G. S. Zijlstra, and B. H. J. Dickhoff. A process for preparing formulations of lipophilic active substances by spray freeze drying. 2005-EP55805, 2006051067, 20051108 (2006).
18. V. V. Boldyrev, T. P. Shakhtshneider, L. P. Burleva, and V. A. Severtsev. Preparation of the disperse systems of sulfathiazole-poly(vinylpyrrolidone) by mechanical activation. Drug Dev. Ind. Pharm. 206:1103-1114 (1994).
19. F. Forni, G. Coppi, V. Iannuccelli, M. A. Vandelli, and M. T. Bernabei. Solid state transitions and CAP availability in surface solid dispersions of chloramphenicol stearate polymorphs. Drug Dev. Ind. Pharm. 145:633-647 (1988).
20. E. Yonemochi, M. Matsumura, T. Oguchi, K. Yamamoto, and Y. Nakai. Interactions of medicinals and porous powder. VI. Stability of aspirin in controlled pore glass solid dispersions. Chem. Pharm. Bull. 394:1027-1031 (1991).
21. M. K. Gupta, A. Vanwert, and R. H. Bogner. Formation of physically stable amorphous drugs by milling with neusilin. J. Pharm. Sci. 923:536-551 (2003).
22. T. Konno, K. Kinuno, and K. Kataoka. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state. I. Effect of vapor pressure of the medicinals on changes in crystalline properties. Chem. Pharm. Bull. 341:301-307 (1986).
23. K. H. Kim, M. J. Frank, and N. L. Henderson. Application of differential scanning calorimetry to the study of solid drug dispersions. J. Pharm. Sci. 743:283-289 (1985).
24. L. Wang, F.-D. Cui, and H. Sunada. Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method. Chem. Pharm. Bull. 541:37-43 (2006).
25. H. Takeuchi, S. Nagira, H. Yamamoto, and Y. Kawashima. Solid dispersion particles of tolbutamide prepared with fine silica particles by the spray-drying method. Powder Technol. 1413:187-195 (2004).
26. A. M. El-Sayed, A. S. Ali, and A. A. Assi. Enhancing the pharmacological effect of phenytoin using porous silica as carrier. STP Pharma 34:319-324 (1993).
27. A. E. Aboutaleb, A. A. Abdel-Rahman, M. O. Ahmed, and U. S. A. Uwaida. Enhancement of dissolution rate of meclozine HCl by co-grinding and loading onto certain adsorbents. Bull. Pharm. Sci. Assiut Univ. 251:7-14 (2002).
28. D. Bahl, and R. H. Bogner. Amorphization of indomethacin by co-grinding with Neusilin US2: Amorphization kinetics, physical stability and mechanism. Pharm. Res. 2310:2317-2325 (2006).
29. M. O'Brien, J. McCauley, and E. Cohen. Indomethacin. In H. G. Brittain (ed.), Analytical Profiles of Drug Substances, 13:ACademic, London, UK, 1984, pp. 211-238.
30. R. K. Iler. The Chemistry of Silica: Solubility, Polymerization, Colloid and Surface Properties and Biochemistry, Wiley, New York, 1979, p 892.
31. M. Mosharraf, and C. Nystrom. The effect of dry mixing on the apparent solubility of hydrophobic, sparingly soluble drugs. Eur. J. Pharm. Sci. 92:145-156 (1999).
32. M. Kinoshita, K. Baba, A. Nagayasu, K. Yamabe, M. Azuma, H. Houchi, and K. Minakuchi. Highly stabilized amorphous 3-bis (4-methoxyphenyl)methylene-2-indolinone (TAS-301) in melt-adsorbed products with silicate compounds. Drug Dev. Ind. Pharm. 295:523-529 (2003).
33. Z. Wang, L. S. Burrell, and W. J. Lambert. Solubility of E2050 at various pH: A case in which apparent solubility is affected by the amount of excess solid. J. Pharm. Sci. 916:1445-1455 (2002).
34. K. Kawakami, K. Miyoshi, and Y. Ida. Impact of the amount of excess solids on apparent solubility. Pharm. Res. 229: 1537-1543 (2005).
35. E. M. Phillips, and P. R. Byron. Surfactant promoted crystal growth of micronized methylprednisolone in trichloromonofluoromethane. Int. J. Pharm. 1101:9-19 (1994).
36. M. Mosharraf, and C. Nystrom. Apparent solubility of drugs in partially crystalline systems. Drug Dev. Ind. Pharm. 296: 603-622 (2003).